Patent ductus arteriosus ligation on neurodevelopmental outcomes at corrected 2 years

Table 1 Clinical characteristics of VLBWIs (n = 191) with PDA

	No surgical ligation (n = 163)	Surgical ligation group (n = 28)	P-value
Gestational age, week	28.2 ± 17.8	27.2 ± 12.7	0.001
Birth weight, g	1070 ± 285	1003 ± 186	0.235
Male, n (%)	140 (85.9)	11(39.3)	0.338
Resuscitation at birth	155 (97.5)	23 (82.1)	0.058
RDS^b	151 (92.6)	25 (92.6)	0.993
Pneumothorax^b	21(12.9)	4 (14.3)	0.839
Pulmonary hemorrhage^b	33 (20.2)	7 (25.0)	0.568
Pulmonary hypertension^a,b	17 (10.4)	12(42.9)	< 0.001
Oral ibuprofen use^b	9 (5.5)	10 (35.7)	< 0.001
Exposure to hs PDA,days^b	7.2 ± 9.6	21.5 ± 24.6	< 0.001
IVH > grade II	17 (19.5)	14 (24.1)	0.053
Neonatal seizure^b	14 (16.1)	20 (34.5)	0.010
Sepsis	60(36.8)	15 (53.6)	0.093
NEC operation	19 (12.0)	4 (14.8)	0.685
ROP laser Treatment	7/156(4.3)	4 (14.8)	0.036
BPD ≥ moderate	19 (21.8)	14 (50.0)	0.004
TPN, days	34.1 ± 28.6	61.5 ± 34.6	0.886
Mechanical ventilation, days^c	20.3 ± 27.8	40.4 ± 38.5	0.026
Hospitalized days ^c	54.7 ± 37.9	76.7 ± 41.2	< 0.001
PVL	64 (43.2)	8 (29.6)	0.186
Mortality	15(9.2)	5(17.8)	0.048

Abbreviations: VLBWI very low birth weight infants, PDA patent ductus arteriosus, g gram body weight, RDS respiratory distress syndrome, IVH intraventricular hemorrhage, NEC necrotizing enterocolitis, ROP retinopathy of prematurity, BPD bronchopulmonary dysplasia, TPN total parental nutrition, PVL periventricular leukomalacia
^aUse of nitrioxide, sildenafil or iloprost within 1 week of birth
^bClinical variables before surgical ligation
^cExpired patients were excluded

ISSN: 1824-7288